Sun Pharma Advanced Research Share Price

Sun Pharma Advanced Research Company Limited is an India-based clinical-stage biopharmaceutical company that focuses on developing therapeutics to improve standards of care for patients worldwide. The Company’s therapeutic focus is in the area of oncology, neurology and immunology. Its lead oncology programs include vodobatinib (SCO-088), a BCR-ABL targeting tyrosine kinase inhibitor for refractory chronic myelogenous leukemia, and an anti-MUC-1 antibody-drug conjugate (ADC) with the potential to treat multiple cancers. The Company’s other programs include Sezaby for the treatment of neonatal seizures, Vodobatinib for the treatment of neurodegenerative disorders (SCC-138), Vibozilimod for the treatment of autoimmune disorders (SCD-044), SCD-153 for the treatment of alopecia areata, SBO-154 for multiple cancer indications and SCO-155 for treatment of cancer. SBO-154 is an anti MUC1 ADC being developed for multiple tumor types expressing MUC1.As of 10 Jun 2026, Sun Pharma Advanced Research share price is ₹207.80. The stock opened at ₹210.26, compared to its previous close of ₹209.19. During today's trading session, Sun Pharma Advanced Research share price moved in the range of ₹206.87 to ₹214.80, with an average price of ₹210.84 for the day. Looking at its last 52-week, the stock has touched a low of ₹206.87 and a high of ₹214.80. On the performance front, Sun Pharma Advanced Research share price has increased by 47.12% over the last six months and is up 25.38% on a year-on-year basis.

The market capitalization of Sun Pharma Advanced Research is ₹6,792 Crs, with a P/E ratio of 4.3 and a dividend yield of 0.00%.